Shockwave has completed the DISRUPT BTK clinical study, demonstrating the effectiveness and safety of IVL in small diameter, difficult-to-treat BTK arteries - no procedural complications, low residual stenosis and no TLR at 30 days in severely calcified CLI patients.
Looking for careers? Click here.
But, right now we're in the early phases of the R&D program. In the meantime, don't miss the IVL application that heart teams are embracing already — maintaining transfemoral TAVR access through heavily calcified iliacs by using IVL.